The role of microparticles in VTE
Cancer-associated venous thromboembolism (VTE) causes significant morbidity and mortality in patients and constitutes...
Most Read
The Management of Cancer-Associated Thrombosis: Are We at a Crossroad?
During this webinar, our three speakers, Professor Anna Falanga, Dr. Florian Scottè, and Dr. Luis Jara Palomares,...
Arterial thromboembolism can also be the first clinical manifestation of a neoplasm
Several studies showed that venous thrombosis can be the first clinical manifestation of an occult neoplasm. For this...
Trial updates In thromboprophylaxis of cancer-related venous thromboembolism
The past decade has seen a large number of studies focusing on identifying cancer patients at high risk for venous...
Lessons from the CATCH study: beware of the risk of bleeding in neoplastic patients treated for VTE
The results of an interesting secondary analysis of the CATCH study were published recently and they are useful for a...
Cancer-Associated Thrombosis: Updates and Controversies
In this webinar, our speakers Prof. Anna Falanga, Prof. Alok A Khorana, and Prof. Benjamin Brenner talked about the...
Risk of thromboembolism in cancer patients with Port-a-Cath. Results and implications of the ONCOCIP study
The normal experience of cancer patients who receive an implantable venous access device (Port-a-Cath) for chemotherapy...
Managing antithrombotic medication in thrombocytopenia
Cancer is associated with an increased risk of venous but also arterial thrombosis1. Moreover, contemporary anticancer...
The safety of DOACs to treat VTE in patients with brain tumors
Patients with primary and metastatic brain tumors have a high risk of venous thromboembolism (VTE), occurring in 20-30%...
An interview with Paolo Prandoni
Paolo Prandoni Department of Cardiac, Thoracic and Vascular Sciences – Università di...